Yes, oseltamivir (Tamiflu) should still be given to patients with influenza A after 5 days of symptom onset if they have comorbid conditions.
For patients with comorbid conditions (high-risk patients), antiviral treatment should be initiated regardless of illness duration, as these patients are at increased risk for severe complications and death. 1
Key Decision Points
Who Gets Treatment After 5 Days?
The IDSA guidelines explicitly state that clinicians should start antiviral treatment for:
- Hospitalized patients of any age, regardless of illness duration prior to hospitalization 1
- Outpatients with severe or progressive illness, regardless of illness duration 1
- Outpatients at high risk of complications from influenza, including those with chronic medical conditions 1
What Qualifies as High-Risk/Comorbid Conditions?
High-risk patients include those with:
- Chronic cardiac disease
- Chronic respiratory disease (COPD, asthma)
- Immunocompromised conditions
- Age ≥65 years or <2 years
- Pregnancy or within 2 weeks postpartum 1
Treatment Duration Considerations
Standard treatment is 5 days of oseltamivir 75 mg twice daily 1, 2. However, longer duration should be considered for immunocompromised patients or those requiring hospitalization for severe lower respiratory disease, as viral replication is often protracted in these populations 1.
Evidence Supporting Late Treatment
Recent research supports this approach. A 2025 cohort study of over 11,000 hospitalized patients demonstrated that oseltamivir treatment was associated with:
- 1.8% absolute reduction in in-hospital mortality
- Earlier discharge from hospital
- Lower 30-day readmission rates 3
One retrospective ICU study found improved survival when oseltamivir was initiated within 5 days of symptom onset in H1N1-infected patients 4, though evidence beyond 48 hours in non-severe outpatients is limited.
Critical Caveats
The 48-hour window is primarily relevant for otherwise healthy outpatients with uncomplicated influenza. For your patient with comorbidities, this window does not apply—the presence of risk factors overrides the timing consideration 1.
Do not delay treatment while awaiting test results in high-risk patients. Start empirically if influenza is suspected clinically during flu season 1.
Monitor for bacterial coinfection, particularly in patients who present with severe disease initially or deteriorate after initial improvement 1.
The FDA label notes that efficacy in patients with chronic cardiac/respiratory disease has not been formally established in trials 2, but this reflects study limitations rather than contraindications. The guideline recommendations are based on the biological rationale that high-risk patients have more to gain from viral suppression, even when started later in illness 1.